Ajinomoto to consolidate pharma operations
This article was originally published in Scrip
The diversified Japanese foods company Ajinomoto will set up a new wholly owned pharmaceutical subsidiary next April 1st in a move which will bring together all its operations in the sector under one roof.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.